![](/img/cover-not-exists.png)
Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer
Duffy, A.G., Makarova-Rusher, O.V., Ulahannan, S.V., Rahma, O.E., Fioravanti, S., Walker, M., Abdullah, S., Raffeld, M., Anderson, V., Abi-Jaoudeh, N., Levy, E., Wood, B.J., Lee, S., Tomita, Y., TrepeVolume:
139
Language:
english
Journal:
International Journal of Cancer
DOI:
10.1002/ijc.30199
Date:
October, 2016
File:
PDF, 1.08 MB
english, 2016